Abstract:High grade serous carcinoma (HGSC) is the most common and the deadliest histologic subtype of epithelial ovarian cancer. HGSC is a therapeutic challenge, as it recurs in 80 % of patients diagnosed, often as chemoresistant disease. The mechanism of this chemoresistance is not fully elucidated, but it is partly attributed to the ability of HGSC to maintain a stem-like phenotype that enables development of resistance to current therapies. Polycomb Repressor Complexes 1 and 2 (PRC1/2) have been implicated in the maintenance of the stem cell compartment through silencing tumor suppressor genes and regulating stem cells. These complexes are comprised of multiple polycomb group (PcG) proteins that play a role in normal development, and when deregulated contribute to the development of cancer [2]. Proteins included in PRC1 include B lymphoma mouse Moloney leukemia virus insertion region (BMI1), RING1, and chromobox (CBX) proteins. We aimed to review each of the protein components of PRC1 and their mechanistic relationships to promoting chemoresistant recurrences and propagation of ovarian cancer. Where possible, we reviewed therapeutic investigations of these proteins. We utilized a scoping literature review through Covidence to identify 42 articles meeting criteria for inclusion. The authors identified four relevant articles and the Yale MeSH Analysis Grid Generator was used to establish additional keywords and heading terms. A medical librarian used these terms and articles to draft an initial search strategy within each of the following databases: MEDLINE, Embase, Cochrane Library, and Web of Science Core Collection, yielding 439 articles based on title and abstract. Abstracts were independently reviewed by the authors, identifying 77 articles for full text review, of which 35 were ultimately excluded, leaving 42 articles for full review. Our review identified the currently known mechanisms of the subunits of PRC1 that contribute to HGSC development, recurrence, and chemoresistance. By compiling a comprehensive review of available scientific knowledge, we support and direct further investigation into PRC1 that can affect meaningful advances in the treatment of HGSC.

Polycomb genes and cancer: Time for clinical application?

Polycomb Directed Cell Fate Decisions in Development and Cancer

Polycomb Group (pcg) Proteins and Human Cancers: Multifaceted Functions and Therapeutic Implications

Polycomb Repressor Complex: Its Function in Human Cancer and Therapeutic Target Strategy.

Polycomb Group Proteins and Their Roles in Carcinogenesis

Clinical Correlations of Polycomb Repressive Complex 2 in Different Tumor Types

Gene Silencing by the Polycomb Group Proteins and Associations with Cancer

The roles of Polycomb repressive complexes in mammalian development and cancer

LncRNA PCGEM1 in Human Cancers: Functions, Mechanisms and Promising Clinical Utility

Pharmacological Advancements of PRC2 in Cancer Therapy: A Narrative Review

Polycomb repressive complex 2 mutations predict survival benefit in advanced cancer patients treated with immune checkpoint inhibitors

Polycomb repressive complex’s evolutionary conserved function: the role of EZH2 status and cellular background

Polycomb Genes, Mirna, and Their Deregulation in B-cell Malignancies.

Polycomb-Like Proteins in Gene Regulation and Cancer

Polycomb repressive complex 2 and its core component EZH2: potential targeted therapeutic strategies for head and neck squamous cell carcinoma

Polycomb Repressor Complex 1 (PRC1) in ovarian cancer: A scoping literature review

Epigenetic regulation of cancer progression by EZH2: from biological insights to therapeutic potential

Combinatorial pharmacologic approaches target EZH2-mediated gene repression in breast cancer cells

EZH1/2 as targets for cancer therapy

EZH2‐associated tumor malignancy: A prominent target for cancer treatment

The Polycomb Repressor Complex 1 Drives Double-Negative Prostate Cancer Metastasis by Coordinating Stemness and Immune Suppression.